A new blood test for amyotrophic lateral sclerosis (ALS) has been developed, providing a highly accurate and expedited diagnostic method. Unlike traditional approaches that can take up to a year and involve extensive clinical examinations, this test only requires a simple blood draw. By analyzing specific microRNA sequences from vesicles released by the brain and nervous system, the test creates a distinct "ALS fingerprint" with up to 98% accuracy. Researchers at Brain Chemistry Labs, as detailed in Brain Communications, hope this innovation will reduce misdiagnosis rates and accelerate treatment.
Validated through studies with 471 patient samples from the U.S. National ALS Biorepository, this new diagnostic tool is poised to enhance early detection and improve treatment outcomes for ALS patients. The test is expected to be widely available to neurologists within 18 to 24 months through…
